naltrexone and B16 Melanoma

naltrexone has been researched along with B16 Melanoma in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Baamonde, A; González-Rodríguez, S; Lastra, A; Machelska, H; Menéndez, L; Seitz, V; Stein, C1
Gao, XH; Griffin, N; Jiao, X; Plotnikoff, NP; Qi, RQ; Shan, FP; Wang, DM1

Other Studies

2 other study(ies) available for naltrexone and B16 Melanoma

ArticleYear
A low pKa ligand inhibits cancer-associated pain in mice by activating peripheral mu-opioid receptors.
    Scientific reports, 2020, 10-29, Volume: 10, Issue:1

    Topics: Analgesics, Opioid; Animals; Bone Neoplasms; Cancer Pain; Cell Line, Tumor; Fentanyl; Hydrogen-Ion Concentration; Hyperalgesia; Ligands; Male; Melanoma, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Morphinans; Naloxone; Naltrexone; Narcotic Antagonists; Piperidines; Receptors, Opioid, mu

2020
Killing effect of methionine enkephalin on melanoma in vivo and in vitro.
    Oncology reports, 2017, Volume: 38, Issue:4

    Topics: Animals; Cell Cycle Checkpoints; Cell Proliferation; Dendritic Cells; Enkephalin, Methionine; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Interferon-gamma; Interleukin-2; Melanoma, Experimental; Mice; Naltrexone; Tumor Burden; Tumor Necrosis Factor-alpha

2017